Health
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce new preclinical data demonstrating significant neuroprotective effects of NUZ-001 and its active metabolite, NUZ-001 Sulfone, in a zebrafish model of Huntington's disease (HD). HD is a rare, inherited neurodegenerative disorder that causes progressive degeneration of motor function, co
About this update from Neurizon Therapeutics Limited
[{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed haemoglobin production, and rescued BDNF expression following Htt protein knockdown","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"Neurizon plans to initiate additional validation studies in mammalian models of Huntington's disease","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"These findings reinforce NUZ-001's potential as a platform therapy targeting core neurodegenerative mechanisms","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":585,"olType":false},{"type":"text","content":"MELBOURNE, Australia, June 16, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce new preclinical data demonstrating significant neuroprotective effects of NUZ-001 and its active metabolite, NUZ-001 Sulfone, in a zebrafish model of Huntington's disease (HD). HD is a rare, inherited neurodegenerative disorder that causes progressive degeneration of motor function, cognition, and mental health.","length":607,"tagName":"p"},{"type":"text","content":"In this disease model of HD, the targeted knockdown of the Htt (huntingtin) protein mRNA knockdown approach, triggers characteristic HD-related deficits, including increased cell death (acridine orange staining), morphological malformations, impaired haemoglobin production (Benzidine staining), and reduced expression of brain-derived neurotrophic factor (BDNF), a critical biomarker of neuronal function and survival. Treatment with NUZ-001 or NUZ-001 Sulfone following Htt knockdown prevented developmental and morphological abnormalities, attenuated neuronal cell death, restored the delayed production of haemoglobin, and rescued BDNF expression, providing evidence of their potentia...